Reference · cited facts
Semaglutide
Ozempic / Wegovy / RybelsusHalf-life ≈7 daysFDA-approvedReviewed July 2026
Educational information and a math tool only — not medical advice, a dose recommendation, or an endorsement of peptide use. Consult a licensed healthcare provider before starting, stopping, or changing anything.
Class / mechanism
Semaglutide is an FDA-approved GLP-1 receptor agonist; the brand names Ozempic, Wegovy and (oral) Rybelsus are referenced for identification only.
SOURCE [1]
Regulatory status
FDA-approved as Ozempic and Rybelsus (type 2 diabetes) and Wegovy (chronic weight management). Prescription only. Approved products are supplied as prefilled pens (Ozempic, Wegovy) or oral tablets (Rybelsus) — not as a powder to reconstitute.
FDA · July 2026
Reported half-life
≈7 days
PUBMED
Human evidence
Established (FDA-approved)
LITERATURE
What the literature reports
- Semaglutide is an FDA-approved GLP-1 receptor agonist; the brand names Ozempic, Wegovy and (oral) Rybelsus are referenced for identification only.
- Its published blood half-life is about 7 days (roughly 165–184 hours), which supports once-weekly injectable dosing.
- FDA-approved semaglutide is supplied ready-to-use as prefilled pens or oral tablets. Reconstitution applies only to lyophilized compounded or research-grade (“research use only”) material, not to the approved products.
Honest caveats
- • This is a prescription medicine — obtain and dose it only through a licensed clinician.
- • FDA-approved products come prefilled; compounded or “research-use-only” versions are not the FDA-approved product.
- • Brand names (Ozempic, Wegovy, Rybelsus) are used for factual reference only — no affiliation or endorsement is implied.
Reconstitution calculator
Enter your own vial size, BAC water and target dose — get exact syringe units.
Sources